Buy Generic Nintedanib Online

Generic Nintedanib Information

Introduction

Nintedanib is a small‑molecule tyrosine‑kinase inhibitor that has become a cornerstone therapy for several progressive fibrotic lung diseases. In Hong Kong, the drug is prescribed for adults with idiopathic pulmonary fibrosis (IPF), systemic sclerosis‑associated interstitial lung disease (SSc‑ILD), and other forms of progressive pulmonary fibrosis (PF‑ILD). It is marketed by Boehringer Ingelheim, belongs to the “general health” medication group, and is available both as a brand‑name product (Ofev) and as a generic formulation.

What is Nintedanib?

Nintedanib is the generic version of Ofev, containing the same active compound Nintedanib. It is an oral, capsule‑form medication that inhibits multiple receptor tyrosine kinases involved in fibroblast proliferation and angiogenesis. Our online pharmacy provides this generic alternative as a cost‑effective treatment option for patients who meet the clinical criteria for therapy.

The drug was originally developed by Boehringer Ingelheim and received its first regulatory approval in the European Union in 2014 for IPF. Subsequent approvals have extended its indication to SSc‑ILD (2019) and to broader PF‑ILD populations (202). In Hong Kong, the Medicines and Poisons Ordinance allows import of the generic product under the same therapeutic standards as the originator.

How Nintedanib Works

Nintedanib blocks the intracellular ATP‑binding sites of several receptor tyrosine kinases, most notably:

• Vascular endothelial growth factor receptors (VEGFR 1‑3)
• Platelet‑derived growth factor receptors (PDGFR α/β)
• Fibroblast growth factor receptors (FGFR 1‑3)

These pathways drive the activation, migration, and proliferation of fibroblasts and the deposition of extracellular matrix in the lung interstitium. By inhibiting these signals, Nintedanib reduces the rate of fibrotic tissue formation, slowing the decline in forced vital capacity (FVC) that characterises progressive interstitial lung disease.

The drug reaches peak plasma concentrations within 2–4 hours after oral ingestion. It is metabolised primarily by esterases, with minor contributions from CYP3A4, and is eliminated in feces (≈ 80 %) and urine (≈ 10 %). The terminal half‑life is about 10–15 hours, supporting twice‑daily dosing.

Conditions Treated with Nintedanib

• Idiopathic Pulmonary Fibrosis (IPF) – a chronic, progressive fibrosing interstitial pneumonia of unknown cause. In Hong Kong, epidemiological surveys estimate an incidence of 8–10 cases per 100,000 adults, with a median survival of 3–5 years without treatment. Nintedanib reduces annual FVC decline by roughly 50 % in pooled phase III trials (INPULSIS‑1/2).
• Systemic Sclerosis‑Associated Interstitial Lung Disease (SSc‑ILD) – lung involvement occurs in 70–80 % of systemic sclerosis patients and is the leading cause of mortality. The SENSCIS trial demonstrated that Nintedanib lowered the rate of FVC loss compared with placebo, offering a disease‑modifying option.
• Progressive Fibrosing Interstitial Lung Disease (PF‑ILD) beyond IPF and SSc‑ILD – a heterogeneous group of non‑IPF interstitial lung diseases that demonstrate a progressive phenotype. The INBUILD trial showed a statistically significant slowing of FVC decline across multiple PF‑ILD subtypes, leading to regulatory approval for this broader indication.

For each condition, the therapeutic goal is to preserve lung function, improve quality of life, and delay the need for lung transplantation.

Who is Nintedanib For?

• Adults diagnosed with IPF confirmed by high‑resolution computed tomography (HRCT) or lung biopsy, and whose disease shows a progressive decline in FVC or worsening symptoms despite optimal supportive care.
• Patients with SSc‑ILD who have at least 10 % predicted FVC loss over 24 months or who display a progressive radiological pattern.
• Individuals with non‑IPF PF‑ILD meeting the criteria of a ≥ 10 % relative decline in FVC over 24 months, worsening respiratory symptoms, or increasing fibrosis on imaging.

Contra‑indications / Situations where Nintedanib is not appropriate

• Severe hepatic impairment (Child‑Pugh C) because of impaired drug metabolism.
• Known hypersensitivity to Nintedanib or any excipients in the capsule formulation.
• Pregnant or breastfeeding women; pre‑clinical data indicate potential fetal toxicity.
• Patients receiving concurrent strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) where dose adjustment is not feasible.

Clinicians must assess kidney and liver function, bleeding risk, and comorbidities before initiating therapy.

Risks, Side Effects, and Interactions

Common

• Diarrhoea – reported in up to 60 % of patients; usually mild to moderate and manageable with dietary modification and antidiarrhoeal agents.
• Nausea / Vomiting – occurs in roughly 20‑30 % of users.
• Abdominal pain – intermittent discomfort, often concurrent with diarrhoea.
• Decreased appetite – may contribute to secondary weight loss.

Rare

• Elevated liver enzymes (ALT/AST) – observed in < 5 % of patients; requires regular monitoring of hepatic function.
• Hypertension – infrequent but documented; blood pressure should be measured periodically.

Serious

• Severe gastrointestinal haemorrhage – rare (< 1 %) but potentially life‑threatening, especially in patients on anticoagulants or antiplatelet agents.
• Serious hepatic injury – rare cases of drug‑induced liver failure have been reported; immediate discontinuation is advised if transaminases > 3 × ULN with symptoms.
• Arterial thromboembolic events – isolated reports of myocardial infarction and stroke; causality remains uncertain, but caution is warranted in high‑risk individuals.

Clinically Relevant Drug–Drug Interactions

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) ↑ Nintedanib exposure → consider dose reduction or avoid.
• P‑glycoprotein (P‑gp) inhibitors (e.g., verapamil, amiodarone) may increase plasma levels.
• Anticoagulants / Antiplatelet agents (warfarin, clopidogrel, DOACs) – additive bleeding risk; monitor coagulation parameters.
• Concomitant use of other anti‑angiogenic agents (e.g., bevacizumab) – potential for enhanced vascular toxicity.

Patients should provide a complete medication list, including over‑the‑counter products and herbal supplements, to the prescribing clinician.

Practical Use: Dosing, Missed Dose, Overdose

• Standard dosing – 150 mg (one capsule) taken orally twice daily, preferably with food to minimise gastrointestinal upset.
• Dose adjustment – If intolerable diarrhoea or liver enzyme elevation occurs, the dose may be reduced to 100 mg twice daily.
• Renal impairment – No dose change is required for mild‑to‑moderate chronic kidney disease (eGFR ≥ 30 mL/min/1.73 m²).
• Hepatic impairment – For moderate impairment (Child‑Pugh B), the recommended dose is 100 mg twice daily; the drug is contraindicated in severe impairment (Child‑Pugh C).

Missed dose – Skip the missed dose and resume the regular schedule at the next prescribed time. Do not double‑dose to compensate.

Overdose – In the event of accidental overdose, seek immediate medical attention or contact a poison‑control centre. Management is primarily supportive, focusing on hydration, monitoring of hepatic function, and treatment of severe diarrhoea or bleeding complications.

Practical precautions

• Take capsules with a full glass of water.
• Food can reduce the incidence of diarrhoea but does not affect drug absorption.
• Avoid alcohol excess, as it may exacerbate gastrointestinal side effects and hepatic stress.
• Regular monitoring (every 4–8 weeks) of liver enzymes, complete blood count, and lung function is recommended during the first 6 months and thereafter as clinically indicated.

Buying Nintedanib from Our Online Pharmacy

Patients in Hong Kong who encounter limited local supply or high out‑of‑pocket costs can obtain generic Nintedanib through our online pharmacy.

• Affordable pricing – We source the medication at near‑manufacturer cost, passing savings directly to the consumer.
• Verified quality – All batches are procured from licensed overseas manufacturers who meet GMP standards; each shipment undergoes third‑party quality verification before dispatch.
• Guaranteed delivery – Discreet packaging is dispatched via express courier (usually within 7 days) or regular airmail (approximately 3 weeks) to any address in Hong Kong.
• Online‑only access – Our pharmacy broker service collaborates with internationally accredited pharmacies, allowing us to provide medicines that may not be stocked in local retail outlets.
• Privacy‑focused – Transactions are encrypted, and no personal health information is displayed on the packaging, ensuring confidentiality for patients who value discretion.

By choosing our platform, eligible adults obtain a reliable supply of Nintedanib without unnecessary financial burden, while remaining compliant with Hong Kong’s import regulations for personal use.

FAQ

• Is Nintedanib available in both brand‑name and generic forms in Hong Kong?
  Yes. The originator product Ofev is sold in Hong Kong, and generic Nintedanib capsules containing the identical active ingredient are also accessible. The generic version offers comparable efficacy at a lower price point.

• What temperature range is suitable for storing Nintedanib capsules?
  Nintedanib should be kept at controlled room temperature, 15 °C to 30 °C (59 °F‑86 °F). Protect the product from direct sunlight, excessive humidity, and freezing conditions.

• Does Nintedanib require refrigeration after opening the bottle?
  No refrigeration is needed. Once the bottle is opened, keep the capsule container tightly closed to prevent moisture ingress and maintain stability.

• Can I travel internationally with Nintedanib in my carry‑on luggage?
  Yes, you may carry the medication in your hand luggage. Keep the original packaging or a pharmacist‑issued label, and ensure the quantity does not exceed 30 days’ supply unless you hold a valid prescription for longer travel.

• Are there any dietary restrictions while taking Nintedanib?
  There are no strict food prohibitions, but taking the capsules with meals reduces the frequency of diarrhoea. High‑fat meals do not markedly affect drug absorption.

• What are the inactive ingredients in the generic capsules?
  Generic Nintedanib capsules typically contain lactose monohydrate, maize starch, magnesium stearate, and titanium dioxide as a coating agent. Patients with specific excipient allergies should verify the exact formulation with the supplier.

• Is Nintedanib classed as a controlled substance in Hong Kong?
  No. Nintedanib is not listed under the Dangerous Drugs Ordinance and therefore does not require a special licence for personal import.

• How does the regulatory approval of Nintedanib differ between the EU and Hong Kong?
  The European Medicines Agency approved Nintedanib for IPF in 2014 and later expanded its indications. Hong Kong’s Department of Health recognized these approvals and granted local registration based on the same clinical data, allowing both brand‑name and generic products to be marketed.

• Can Nintedanib be used in patients with mild hepatic dysfunction?
  For mild to moderate hepatic impairment (Child‑Pugh A‑B), dosage reduction to 100 mg twice daily is recommended. Severe hepatic failure (Child‑Pugh C) is a contraindication, as clearance is markedly reduced.

• Does Nintedanib interact with common herbal supplements such as St. John’s wort?
  St. John’s wort is a known CYP3A4 inducer and may lower Nintedanib plasma concentrations, potentially diminishing efficacy. Patients using such supplements should discuss alternatives with their healthcare provider.

• What is the typical time frame for observing a clinical response to Nintedanib?
  The drug’s anti‑fibrotic effect is gradual; most clinical trials reported a measurable reduction in FVC decline after 12 weeks, with continued benefit observed over 1 year of therapy.

• Are there differences in tablet appearance between the brand‑name and generic versions?
  Yes. Ofev capsules are orange‑coloured with a distinct imprint, whereas the generic version may appear white or off‑white with a different imprint code. The active content, however, remains identical.

• Can Nintedanib be safely taken by patients with chronic kidney disease stage 3?
  Nintedanib does not require dose adjustment for eGFR ≥ 30 mL/min/1.73 m², which includes stage 3 CKD. Renal function should still be monitored periodically.

• Is there any guidance on alcohol consumption while on Nintedanib?
  Moderate alcohol intake is not prohibited, but excessive consumption may exacerbate liver enzyme elevations and gastrointestinal side effects. Patients should limit intake and avoid binge drinking.

Glossary

Tyrosine‑Kinase Inhibitor (TKI)

A class of drugs that block enzymes called tyrosine kinases, which transmit signals that promote cell growth, division, and survival. In Nintedanib, inhibition reduces fibroblast activity that drives lung scarring.

Forced Vital Capacity (FVC)

The maximum amount of air a person can forcefully exhale after a full inhalation, measured in milliliters. Decline in FVC is a key marker of disease progression in interstitial lung diseases.

Child‑Pugh Score

A clinical scoring system that evaluates the severity of chronic liver disease based on bilirubin, albumin, INR, ascites, and encephalopathy. Scores classify hepatic impairment as A (mild), B (moderate), or C (severe).

Gastrointestinal Haemorrhage

Bleeding that originates in the stomach, intestines, or colon. In the context of Nintedanib, the risk is heightened when combined with anticoagulant medications.

⚠️ Disclaimer

The information provided about Nintedanib is for general knowledge only. It does not replace professional medical consultation. All treatment decisions should be made under the supervision of a qualified healthcare provider. We assume all readers are responsible adults capable of making informed decisions about their health. Our online pharmacy offers access to Nintedanib for individuals who may have limited availability through traditional pharmacies, prescription‑based insurance schemes, or who are seeking affordable generic alternatives. Always consult your doctor before starting, changing, or discontinuing any medication.